SPRUCE BIOSCIENCES, INC. 8K

Spruce Biosciences reported Q2 2026 results, outlined late-2026 regulatory and clinical milestones for TA-ERT, disclosed a $5.5 million patient-advocacy investment for an Expanded Access Program, and announced new senior medical leadership appointments.

Spruce Biosciences, Inc. reported its unaudited financial results for the quarter ended June 30, 2026, highlighting a cash balance of $96.3 million expected to fund operations into the second half of 2027, a quarterly net loss of $16.2 million driven primarily by increased R&D and pre-launch G&A expenses, and progress on its lead candidate TA-ERT for MPS IIIB, including plans to submit a Biologics License Application and initiate the FDA-requested TrAnsform confirmatory study in the fourth quarter of 2026. The company also announced a $5.5 million strategic investment from patient advocacy groups Cure Sanfilippo Foundation and the National MPS Society to partially fund a U.S. Expanded Access Program for TA-ERT, and strengthened its leadership team with the appointments of Adrian Quartel, M.D., as Chief Medical Officer effective July 27, 2026, and Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development effective August 3, 2026.

Filing Facts

CIK

1683553

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-345874

Alert Tier

6